Cure Today2d
Looking Ahead After Kisqali’s FDA Approval for Adjuvant Treatment of Early Breast Cancer
Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...
Targeted Oncology1d
No OS Difference Among First-Line CDK4/6 Inhibitors in HR+/HER2- mBC
Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...
Cure Today1d
Camizestrant Plus Kisqali May Be Safe, Effective in ER+/HER2- Breast Cancer
Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...
Medindia1d
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the duration of treatment in ...
Zacks.com on MSN14d
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a ...
PMLiVE14d
Novartis’ Kisqali receives EC approval to treat early breast cancer patients
Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...
Pharmabiz14d
Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR) ...
Daily14d
Novartis Kisqali gets European Commission nod in patients with HR+/HER2-early breast cancer at high risk of recurrence
Basel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an ...
Business Insider15d
Novartis Kisqali Receives EU Approval For HR+/HER2- Early Breast Cancer At High Recurrence Risk
(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone ...